Floatz logo

Pembrolizumab

Neoplasm, Neuroepithelial

DNAtrix, Inc.monoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neoplasm, Neuroepithelial cohort.

Asset / SponsorPhaseRating
TASADENOTUREV
DNAtrix, Inc.
Phase 2B
FILGRASTIM
St. Jude Children's Research Hospital
Phase 1CCC
Interleukin-12
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2CCC
Sonidegib
St. Jude Children's Research Hospital
Phase 1CC
gsk1120212
St. Jude Children's Research Hospital
Phase 1CC

View all 15 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →